Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.

The digital advertising industry is expanding at 10% annually, providing a long-term growth opportunity for DoubleVerify.

JP Morgan sees pricing efforts at Lamb Weston continuing, but warns demand may lag supply amid ongoing industry imbalances.

Genovese upgrades COHR to Buy, lowers price target to $85. Bullish on transceiver market and new CEO. Expects growth in 800G sales in Sept. and Dec.

Find out which companies Benzinga readers should be taking a look at. This week strikes gold, plus real estate and more.

Swedish fintech giant Klarna has postponed its U.S. IPO, citing market instability following new tariff announcements. The ...